Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 6:37 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1609–1632 of 5,153 matching trials from the live ClinicalTrials.gov search.
Conditions
Recurrent Glioma, High-grade Meningioma, Brain Metastasis
Interventions
Panobinostat, Stereotactic body radiation therapy, Quality-of-life assessment, Stereotactic radiosurgery
Drug · Radiation · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Craniopharyngioma, Child, Craniopharyngioma, Recurrent Craniopharyngioma
Interventions
Tovorafenib
Drug
Lead sponsor
Sabine Mueller, MD, PhD
Other
Eligibility
1 Year to 39 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
15
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 12 more
Conditions
Glioblastoma Multiforme, Anaplastic Astrocytoma
Interventions
Bevacizumab and Carboplatin
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
1
States / cities
New York, New York
Conditions
Choroidal Melanoma, Indeterminate Lesions of Eye
Interventions
Not listed
Lead sponsor
Aura Biosciences
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
16
States / cities
Tucson, Arizona • Los Angeles, California • Palo Alto, California + 13 more
Conditions
Neuroendocrine Tumor, Gastrointestinal Neoplasm
Interventions
XmAb18087
Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
12 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
16
States / cities
Phoenix, Arizona • Duarte, California • Los Angeles, California + 13 more
Conditions
Pigmented Skin Lesion, Melanoma
Interventions
Functional photoacoustic microscopy, Standard of care surgical excision, Single cell photoacoustic microscopy
Device · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Adult Glioblastoma, High Grade Glioma, WHO Grade III or IV Malignant Glioma
Interventions
Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP liposome vaccine administered intravenously (RNA loaded lipid particles, RNA-LPs)
Biological
Lead sponsor
University of Florida
Other
Eligibility
4 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Gainesville, Florida
Terminated Phase 2 Interventional Results available

Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma

NCT03476174
Conditions
Melanoma
Interventions
Pembrolizumab, Interleukin-2
Drug
Lead sponsor
Ralph Hauke
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Omaha, Nebraska
Conditions
Recurrent Melanoma, Stage IV Skin Melanoma
Interventions
NA17.A2 Peptide Vaccine, Recombinant MAGE-3.1 Antigen, Recombinant Interleukin-12, MART-1 Antigen, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Glioblastoma
Interventions
Magnetic Resonance Imaging (MRI)
Radiation
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Charleston, South Carolina
Conditions
Neoplasm Metastasis, Brain Neoplasms
Interventions
Motexafin gadolinium
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
9
States / cities
Phoenix, Arizona • Aurora, Colorado • Cleveland, Ohio + 6 more
Conditions
BRAF or NRAS Mutant Metastatic Melanoma
Interventions
MEK162
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
10
States / cities
Fayetteville, Arkansas • Tampa, Florida • Portland, Oregon + 3 more
Conditions
Cancer of Pancreas, Cancer of Liver, Cancer of Rectum, Cancer of Colon, Cancer, Gall Bladder, Myeloma Multiple, Glioblastoma Multiforme
Interventions
Cannabidiol, Bortezomib, Leucovorin, 5-FU, Oxaliplatin, Bevacizumab, Irinotecan, Gemcitabine, Temozolomide
Drug
Lead sponsor
Leaf Vertical Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Orlando, Florida
Conditions
Melanoma
Interventions
GM-CSF DNA, NSC 683472 gp100: 209-217(210M), NSC 699048 Tyrosinase: 368-376(370D)
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
New York, New York
Conditions
Melanoma, Non-Small Cell Lung Cancer, Bladder Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Renal Cancer, Head and Neck Cancer, Other Solid Cancers
Interventions
Autogene cevumeran, Atezolizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
15
States / cities
Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 10 more
Conditions
Merkel Cell Carcinoma
Interventions
Pembrolizumab (MK-3475)
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
12 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
New York, New York
Conditions
Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
Interventions
RMC-6236
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
754 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
21
States / cities
Orange, California • Santa Monica, California • Tampa, Florida + 16 more
Conditions
Melanoma
Interventions
pBCAR3-phosphopeptide, pIRS2-phosphopeptide, 2-MpP (pBCAR3-phosphopeptide + pIRS2-phosphopeptide)
Biological
Lead sponsor
Craig L Slingluff, Jr
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Astrocytoma, IDH-Mutant, Grade 3
Interventions
Intensity-Modulated Radiation Therapy, Volume Modulated Arc Therapy, Pencil Beam Scanning, Intensity-Modulated Proton Therapy, Temozolomide, Vorasidenib, Placebo Administration, Biospecimen Collection, Magnetic Resonance Imaging, Questionnaire Administration
Radiation · Procedure · Drug + 1 more
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
12 Years and older
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2040
U.S. locations
177
States / cities
Phoenix, Arizona • Anaheim, California • Bakersfield, California + 140 more
Conditions
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Neoplasm
Interventions
Bendamustine Hydrochloride, Quality-of-Life Assessment
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
3
States / cities
Chicago, Illinois • Salt Lake City, Utah • Seattle, Washington
Conditions
Melanoma (Skin)
Interventions
aldesleukin, dendritic cell-gp100-MART-1 antigen vaccine
Biological
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Conditions
Melanoma (Skin)
Interventions
dendritic cell-MART-1 peptide vaccine
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Locally Advanced Neuroendocrine Neoplasm, Metastatic Neuroendocrine Neoplasm
Interventions
Placebo Administration, Questionnaire Administration, Telotristat Ethyl
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Houston, Texas
Conditions
Glioblastoma
Interventions
L19TNF, Lomustine
Drug
Lead sponsor
Philogen S.p.A.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
9
States / cities
Chicago, Illinois • Boston, Massachusetts • New York, New York + 4 more